Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 169M | 28M | 0 | 0 | 22M |
| Gross Profit | 154M | 27M | 0 | 0 | 17M |
| Operating Income | -42M | -138M | -99M | -86M | 6M |
| EBITDA | -36M | -149M | -98M | -82M | 10M |
| Net Income | -49M | -160M | -137M | -77M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$21.64
+0.00% today
Window Change
+126.83%
Window
Jun 23, 2025 → Feb 13, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 164 bars · Jun 23, 2025 → Feb 13, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Avadel Pharmaceuticals plc (AVDL) is a Healthcare stock with a market cap of $2.12B. The stock last traded around $21.64 and up 126.8% across the available one-year price window (Jun 23, 2025 → Feb 13, 2026). Baseline metrics include revenue growth of +504.8%, EPS growth of +74.5%, a dividend yield of 0.0%. What stands out right now is revenue +504.8%, EPS +74.5%, free cash flow +63.5% with operating margin 1.8% and ROIC 0.3%. Valuation already assumes a fairly strong business story at price/sales 8.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines AVDL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
AVDL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
AVDL Max Drawdown
-13.74%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for AVDL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$22.3M
FY Net Income
$7.0M
+109.1% YoY
Free Cash Flow
-$48.8M
+36.9% YoY
Revenue Growth
+504.8%
EPS Growth
+74.5%
Gross Margin
94.5%
Net Margin
-0.1%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 169M | 28M | 0 | 0 | 22M |
| Gross Profit | 154M | 27M | 0 | 0 | 17M |
| Operating Income | -42M | -138M | -99M | -86M | 6M |
| EBITDA | -36M | -149M | -98M | -82M | 10M |
| Net Income | -49M | -160M | -137M | -77M | 7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 51M | 31M | 74M | 51M | 72M |
| Total Assets | 164M | 165M | 133M | 247M | 312M |
| Total Liabilities | 90M | 77M | 154M | 169M | 149M |
| Shareholder Equity | 74M | 88M | -21M | 78M | 162M |
| Total Debt | 2M | 3M | 131M | 145M | 131M |
| Net Debt | -50M | -29M | 57M | 94M | 59M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
49M
+37.0% YoY
Capital Expenditures
98K
-276.9% YoY
Free Cash Flow
49M
+36.9% YoY
Key ratios
Gross Margin
94.5%
Operating Margin
1.8%
Net Margin
-0.1%
ROE
-0.3%
Debt / Equity
0.38x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.